Podcasts about dosimetry

Send us a textIn this Journal of Vascular and Interventional Radiology (JVIR) audio episode, JVIR blog Editor Peter Li, MD, MS, uses artificial intelligence (AI) platform ElevenLabs to produce a podcast discussion on the November 2024 JVIR paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original articleRead the blog entry, "Vox Voxel: Calculating Y90 Tumor Dose and Sphere Distribution with Voxel Dosimetry"SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Of all the topics covered during interventional radiology training, dosimetry education is often delayed until after IRs enter clinical practice. In this episode, Drs. Tyler Sandow and Sabeen Dhand host a roundtable discussion with experts on the dosimetry fundamentals that all Y90 operators should understand. They are joined by interventional radiologists Drs. Zachary Berman, Kirema Garcia-Reyes, and Siddharth Padia, who provide their expert insights. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125736 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS The group agrees that dosimetry is not a one-size-fits-all approach. Dosing strategies depend on factors such as tumor size, perfusion territory, underlying liver function, the choice between glass versus resin spheres, and treatment intent. These considerations are illustrated with real-life case examples. The doctors also explore voxel-based dosimetry, a method for calculating the amount of radiation absorbed by different parts of the tumor. They stress the importance of learning how to perform accurate dosage calculations. Finally, the conversation touches on data from major Y90 trials, current guidelines, and the evolving perspective on Y90 as a potential curative treatment, rather than merely a bridging therapy. --- TIMESTAMPS 00:00 - Introduction 01:59 - Dosimetry Education During Training 05:46 - Benefit of Individualized Dosing 11:01 - Complications from High Doses 15:19 - Dosage Calculation Cases 22:51 - Duration of Response to Y90 25:00 - Dosing Based on Treatment Intent 29:11 - Challenging Case Example 42:31 - Voxel-Based Dosimetry 45:15 - Using Dosimetry Software --- RESOURCES LEGACY Trial (Salem et al, 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8596669/ Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma (Pianka et al, 2024): https://pubmed.ncbi.nlm.nih.gov/38913189/ RAPY90D Trial (Kappadath et al, 2023): https://jnm.snmjournals.org/content/64/supplement_1/P268 Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group (Salem et al, 2023): https://pubmed.ncbi.nlm.nih.gov/36114872/ International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres (Levillain, 2021): https://link.springer.com/article/10.1007/s00259-020-05163-5)

"'If we know activity, or sphere activity, at the time of delivery, and we know the dose to tumor, and we know the dose that we gave, we could figure out where the sphere concentrations are ... but we'd need to figure out what the dose to tumor is.' And he was like, 'Just do it in Simplicit90Y.' And at that point it was basically like, 'Oh, boom—just use the dosimetry tool we have to solve a problem. And so, that's where we are."—Tyler Sandow, MD In this Journal of Vascular and Interventional Radiology (JVIR) audio episode, lead author Tyler Sandow, MD, speaks with journal Managing Editor Ana Lewis about his November 2024 paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original article, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kelley Nunez, PhD, Richard Tramel, MD, Patrick Gilbert, MD, Brianna Oliver, MD, Michael Cline, MD, Kirk Fowers, PhD, Ari Cohen, MD, and Paul Thevenot, PhDRead the related commentary, "Known Unknowns: Gaps in Dose Distribution in Radioembolization, and in Our Understanding of Them," by A. Kyle Jones, MDRead the authors' response, "The Sphere Conundrum: Author's Reply to Commentary on Voxel-Based Dosimetry with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kirk Fowers, PhD, and Paul Thevenot, PhDSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

GUEST: Jason Lewis, New YorkIn this episode we discuss and learn about new PSMA-binding ligands with 161Tb, their biodistribution, dosimetry, preclinical therapy, and their comparison with conventional PSMA ligands. Our guest is one of the leading scientists in radiochemistry for cancer detection and therapy, the wonderful Jason Lewis. We talk about the importance of using 161Tb - this novel radionuclide for radioligand therapy - and its favorable decay characteristics as compared to 177Lu. We learn about the added value of the emission of Auger electrons which can effectively eliminate micro-metastasis and when combined with ibuprofen-based PSMA ligands offering albumin-binding properties, tumor uptake and therapeutic efficacy are significantly boosted. Besides this fascinating science, don't miss some very important advice from a very successful scientist in a very competitive environment about work-life balance, prioritising expectations and goals - just never forget to "smell the roses"…Selected Publication: Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy. Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller. Journal of Nuclear Medicine Jul 2023, jnumed.123.265524; DOI: 10.2967/jnumed.123.265524https://jnm.snmjournals.org/content/early/2023/07/13/jnumed.123.265524Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

This recording features audio versions of July 2023 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Short-Term Effects of Genicular Artery Embolization on Symptoms and Bone Marrow Abnormalities in Patients with Refractory Knee Osteoarthritis ReadReal-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Artery Disease ReadMedian Arcuate Ligament Compression Associated with Flow-Related Visceral Aneurysms ReadPregnancy Rate and Outcomes following Uterine Artery Embolization for Uterine Arteriovenous Malformations: A Systematic Review and Meta-Analysis ReadResolution of Pain after Percutaneous Image-Guided Cryoablation of Extraperitoneal Endometriosis ReadYttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres ReadJVIR and SIR thank all those who helped record this episode:Host and audio editor:Rommell Noche, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAbstract readers:Jamie Lee, A.T. Still University School of Osteopathic Medicine, ArizonaManbir Sandhu, University of California Riverside School of MedicineAnna Hu, George Washington University School of Medicine and Health Sciences, D.C.Emily Barr, MBA, Burrell College of Osteopathic Medicine at New Mexico State UniversityIsabelle Barbosa, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutPriya Gupta, MD, Henry Ford Hospital, Michigan ©  Society of Interventional RadiologySupport the show

Dr. Jean-Mathieu Beauregard and Dr. Carlos Uribe discuss the present, future, and implications of dosimetry with moderator Dr. John Sunderland.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.28.534386v1?rss=1 Authors: Zhou, Y.-P., Wilks, M. Q., Dhaynaut, M., Guehl, N. J., Moon, S.-H., El Fakhri, G., Normandin, M. D., Brugarolas, P. Abstract: Purpose: 4-Aminopyridine (4AP) is a medication for the symptomatic treatment of multiple sclerosis. Several 4AP-based PET tracers have been developed for imaging demyelination. In preclinical studies, [11C]3MeO4AP has shown promise due to its high brain permeability, high metabolic stability, high plasma availability, and high in vivo binding affinity. To prepare for the translation to human studies, we developed a cGMP-compliant automated radiosynthesis protocol and evaluated the whole-body biodistribution and radiation dosimetry of [11C]3MeO4AP in non-human primates (NHPs). Methods: Automated radiosynthesis was carried out using a GE TRACERlab FX-C Pro synthesis module. One male and one female adult rhesus macaques were used in the study. A high-resolution CT from cranial vertex to knee was acquired. PET data were collected using a dynamic acquisition protocol with 4 bed positions and 13 passes over a total scan time of ~150 minutes. Based on the CT and PET images, volumes of interest (VOIs) were manually drawn for selected organs. Non-decay corrected time-activity curves (TACs) were extracted for each VOI. Radiation dosimetry and effective dose were calculated from the integrated TACs using OLINDA software. Results: Fully automated radiosynthesis of [11C]3MeO4AP was achieved with 7.3 {+/-} 1.2 % (n = 4) of non-decay corrected radiochemical yield within 38 min of synthesis and purification time. [11C]3MeO4AP distributed quickly throughout the body and into the brain. The organs with highest dose were the kidneys. The average effective dose of [11C]3MeO4AP was 4.27 {+/-} 0.57 Sv/MBq. No significant changes in vital signs were observed during the scan. Conclusion: The cGMP compliant automated radiosynthesis of [11C]3MeO4AP was developed. The whole-body biodistribution and radiation dosimetry of [11C]3MeO4AP was successfully evaluated in NHPs. [11C]3MeO4AP shows lower average effective dose than [18F]3F4AP and similar average effective dose as other carbon-11 tracers. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Dosimetry for everyone! Panel discussionWe discuss the hot topic of dosimetry for theranostics. Much debate around. Apologies on the length of this one, but its worthy of a long discussion.1. Do we need to do it before doing therapy?2. Can we do it?3. But there are problems with it?4. How to get started?and much more https://www.nuccast.com  Nuccast.com #UniversityofMelbourne #ANZSNM #NIF #PET #NuclearMedicine #Podcast #MolecularMedicine #radiochemistry  #theragnostics #tracers #Prostate #cancerNuccast.com ,UniversityofMelbourne ,SNMMI ,NIF  ,PET ,NuclearMedicine ,Podcast ,MolecularMedicine, radiochemistry, theragnostics, tracers, Prostate, cancer@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.

Dosimetry for everyone! Panel discussionWe discuss the hot topic of dosimetry for theranostics. Much debate around. Apologies on the length of this one, but its worthy of a long discussion.1. Do we need to do it before doing therapy?2. Can we do it?3. But there are problems with it?4. How to get started?and much more https://www.nuccast.com  Nuccast.com #UniversityofMelbourne #ANZSNM #NIF #PET #NuclearMedicine #Podcast #MolecularMedicine #radiochemistry  #theragnostics #tracers #Prostate #cancerNuccast.com ,UniversityofMelbourne ,SNMMI ,NIF  ,PET ,NuclearMedicine ,Podcast ,MolecularMedicine, radiochemistry, theragnostics, tracers, Prostate, cancer@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.

Dosimetry for everyone! Panel discussionWe discuss the hot topic of dosimetry for theranostics. Much debate around. Apologies on the length of this one, but its worthy of a long discussion.1. Do we need to do it before doing therapy?2. Can we do it?3. But there are problems with it?4. How to get started?and much more https://www.nuccast.com  Nuccast.com #UniversityofMelbourne #ANZSNM #NIF #PET #NuclearMedicine #Podcast #MolecularMedicine #radiochemistry  #theragnostics #tracers #Prostate #cancerNuccast.com ,UniversityofMelbourne ,SNMMI ,NIF  ,PET ,NuclearMedicine ,Podcast ,MolecularMedicine, radiochemistry, theragnostics, tracers, Prostate, cancer@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.

Dosimetry for everyone! Panel discussionWe discuss the hot topic of dosimetry for theranostics. Much debate around. Apologies on the length of this one, but its worthy of a long discussion.1. Do we need to do it before doing therapy?2. Can we do it?3. But there are problems with it?4. How to get started?and much more https://www.nuccast.com  Nuccast.com #UniversityofMelbourne #ANZSNM #NIF #PET #NuclearMedicine #Podcast #MolecularMedicine #radiochemistry  #theragnostics #tracers #Prostate #cancerNuccast.com ,UniversityofMelbourne ,SNMMI ,NIF  ,PET ,NuclearMedicine ,Podcast ,MolecularMedicine, radiochemistry, theragnostics, tracers, Prostate, cancer@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.

Dr Akila Viswanathan speaks to Dr Robert Hobbs about his research into radiopharmaceuticals, alpha particle therapy and dosimetry based treatment.

In this Episode, Andrea and Sean discuss the report from AAPM TG-218, “Tolerance limits and methodologies for IMRT measurement-based verification QA.” They review some of the TG Report, the report recommendations, and the background of IMRT QA. The hosts share their thoughts and experiences on the IMRT QA process and its impact on clinical outcomes.Have any questions or comments? Talk to us at https://www.reddit.com/r/HormesisPodcast/comments/cgsys3/episode_3_the_definition_of_insanityand_tg218/Miften et al. “Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM TG-218.” Med Phys. 45(4). 2018. [DOI: 10.1002/mp.12810]Low et al. “Dosimetry tools and techniques for IMRT.” Med Phys. 38(3). 2011. [DOI: 10.1118/1.3514120]Ezzel et al. “IMRT commissioning: Multiple institution planning and dosimetry comparison, a report of AAPM TG-119.” Med Phys. 36(11). 2009. [DOI: 10.1118/1.3238104]Nelms et al. “Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors.” Med Phys. 38(2). 2011. [DOI: 10.1118/1.3544657]

Dosimetry, The Second Reason For Holiness, July 29, 2018 by Christian Life Tabernacle - Memphis

Dr Matthew Schloneger is the 2017 winner of the Van Lawrence Fellowship. He is a tenor and a professional singer. He got into voice science while doing his doctoral work in voice pedagogy at the University of Kansas. Through his doctoral work he got into an area of research called voice dosimetry. Voice Dosimetry has to do with vocal health and how we use our voices. Dr. Schloneger is a voice teacher at Friends University in Wichita Kansas.    Take Aways: Matt is really passionate about helping young singers develop in a strong, healthy way.   Voice dosimetry is the study of how we use our voices using real-time technological feedback in a natural setting.  The point of voice dosimetery (and we are still in the early stages of learning from this technology) is to learn about how we can best use and train our voices.   If you are an aspiring singer, be attentive to your overall voice use and remember that you have only one larynx. Vocal hygiene and voice care are essential to your success as a singer, and that includes both good speaking habits and how much you  use your voice overall. If you have an intensive singing week coming up, you may need to think about avoiding loud environments where you will speak a lot at loud volumes(yes, I mean raging parties). If you are preparing a major role or a recital, you need to practice regularly and methodically in order to build up your stamina. Treat your voice with respect, and it will treat you well!   contact: mattschloneger@gmail.com   Every Sing on Facebook: https://www.facebook.com/groups/1711090705861666/   Every Sing on Twitter: @Every_Sing_Pod   Nancy's website: NancyBos.net  

Dr Russo talks to ecancertv at the 3rd ESTRO forum in Barcelona about how physicists accurately measure a dose inside small beam dosimetry. She also discusses stereotactic body radiation therapy (SBRT) techniques.

Many of today’s medical dosimetrists are graduates of the Medical Dosimetry baccalaureate program with MD Anderson’s School of Health Professions.

This is Part III of a podcast series on dental and orthodontic x-rays. This provides an update of the information covered in Part I and Part II. It reviews x-ray dosimetry, which is the calculation of the absorbed dose in human tissue resulting from the exposure to ionizing x-ray radiation. Dosimetry can be a confusing subject for even the savviest of orthodontists. Unknown to many, recent advances in CBCT technology have reduced x-ray exposure to patients considerably. And although there is a common misconception that CBCT imaging dramatically increases the exposure risk when compared to conventional two-dimensional orthodontic imaging, recent data shows there is minimal difference. In fact, when the truth about risk quantification is added to the equation, both orthodontists and dentists alike should be put at ease when it comes to their exposure liability.

Prostate

This is Part I of a three part series on dental and orthodontic x-rays. It is an excerpt from a 2010 lecture given by Dr. Sean K. Carlson at the North East Society of Orthodontists meeting in Montreal, Canada 2010. It covers some basics of x-ray dosimetry as they relate to common dental and orthodontic diagnostic procedures. It also covers the current recommendations by the International Commission on Radiological Protection (ICRP). To ensure patient protection, the risks associated with dental x-rays should be minimized by all practitioners. This Podcast describes the risk relationships between everyday background radiation exposure, radiation exposure of common events like air travel, and radiation exposure from dental and orthodontic x-ray imaging (including 3-D CBCT x-rays). Viewers will be relieved to learn that radiation exposure in the dental office is minimal when compared with the common things we do everyday.

Background: The increase in numbers of mobile phone users was accompanied by some concern that exposure to radiofrequency electromagnetic fields (RF EMF) might adversely affect acute health especially in children and adolescents. The authors investigated this potential association using personal dosimeters. Methods: A 24-hour exposure profile of 1484 children and 1508 adolescents was generated in a population-based cross-sectional study in Germany between 2006 and 2008 (participation 52%). Personal interview data on socio-demographic characteristics, self-reported exposure and potential confounders were collected. Acute symptoms were assessed twice during the study day using a symptom diary. Results: Only few of the large number of investigated associations were found to be statistically significant. At noon, adolescents with a measured exposure in the highest quartile during morning hours reported a statistically significant higher intensity of headache (Odd Ratio: 1.50; 95% confidence interval: 1.03, 2.19). At bedtime, adolescents with a measured exposure in the highest quartile during afternoon hours reported a statistically significant higher intensity of irritation in the evening (4(th) quartile 1.79; 1.23, 2.61), while children reported a statistically significant higher intensity of concentration problems (4(th) quartile 1.55; 1.02, 2.33). Conclusions: We observed few statistically significant results which are not consistent over the two time points. Furthermore, when the 10% of the participants with the highest exposure are taken into consideration the significant results of the main analysis could not be confirmed. Based on the pattern of these results, we assume that the few observed significant associations are not causal but rather occurred by chance.

Transcript --

Transcript --

Background: Despite the increase of mobile phone use in the last decade and the growing concern whether mobile telecommunication networks adversely affect health and well-being, only few studies have been published that focussed on children and adolescents. Especially children and adolescents are important in the discussion of adverse health effects because of their possibly higher vulnerability to radio frequency electromagnetic fields. Methods: We investigated a possible association between exposure to mobile telecommunication networks and wellbeing in children and adolescents using personal dosimetry. A population-based sample of 1.498 children and 1.524 adolescents was assembled for the study (response 52%). Participants were randomly selected from the population registries of four Bavarian (South of Germany) cities and towns with different population sizes. During a Computer Assisted Personal Interview data on participants' well-being, socio-demographic characteristics and potential confounder were collected. Acute symptoms were assessed three times during the study day (morning, noon, evening). Using a dosimeter (ESM-140 Maschek Electronics), we obtained an exposure profile over 24 hours for three mobile phone frequency ranges (measurement interval 1 second, limit of determination 0.05 V/ m) for each of the participants. Exposure levels over waking hours were summed up and expressed as mean percentage of the ICNIRP (International Commission on Non-Ionizing Radiation Protection) reference level. Results: In comparison to non-participants, parents and adolescents with a higher level of education who possessed a mobile phone and were interested in the topic of possible adverse health effects caused by mobile telecommunication network frequencies were more willing to participate in the study. The median exposure to radio frequency electromagnetic fields of children and adolescents was 0.18% and 0.19% of the ICNIRP reference level respectively. Conclusion: In comparison to previous studies this is one of the first to assess the individual level of exposure to mobile telecommunication networks using personal dosimetry, enabling objective assessment of exposure from all sources and longer measurement periods. In total, personal dosimetry was proofed to be a well accepted tool to study exposure to mobile phone frequencies in epidemiologic studies including health effects on children and adolescents.

Tue, 1 Jan 1985 12:00:00 +0100 https://epub.ub.uni-muenchen.de/8818/1/8818.pdf Kellerer, Albrecht M.

Sat, 1 Jan 1983 12:00:00 +0100 https://epub.ub.uni-muenchen.de/8724/1/8724.pdf Kellerer, Albrecht M.